UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Journal of clinical oncology, 2012-02, Vol.30 (5), p.488-496

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

Journal of clinical oncology, 2011-03, Vol.29 (7), p.909-916

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Clinical cancer research, 2012-06, Vol.18 (11), p.3163-3169

2012

Link zum Volltext

Verfügbarkeit prüfen

Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management

Anticancer research, 2014-07, Vol.34 (7), p.3739-3746

2014

Link zum Volltext

Verfügbarkeit prüfen

Force relaxes before the fall of cytosolic calcium in the photomechanical response of rat sphincter pupillae

American Journal of Physiology: Cell Physiology, 2000-07, Vol.279 (1), p.C274-C280

2000

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.169-169

2016

Link zum Volltext

Verfügbarkeit prüfen

ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8014-8014

2015

Link zum Volltext

Verfügbarkeit prüfen

Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.182-182

2016

Link zum Volltext

Verfügbarkeit prüfen

Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.350-350

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract B216: Exposure-response (E-R) relationship of ABT-263-induced thrombocytopenia in cancer patients in phase 1 studies

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.B216-B216

2009

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics, Pharmacodynamics, and Activity of Navitoclax, a Targeted High Affinity Inhibitor of BCL-2, in Lymphoid Malignancies

The lancet oncology, 2010-11, Vol.11 (12), p.1149-1159

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3738: Exploratory patient (pt) stratification markers associated with sensitivity to ABT-263 in small cell lung cancer (SCLC)

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3738-3738

2010

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Refractory or Relapsed Lymphoid Malignancies

Blood, 2007-11, Vol.110 (11), p.1371-1371

2007

Link zum Volltext

Verfügbarkeit prüfen

Force relaxes before the fall of cytosolic calcium in the photomechanical response of rat sphincter pupillae

American Journal of Physiology: Cell Physiology, 2000-07, Vol.48 (1), p.C274-C280

2000

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant Enzalutamide Prior to Prostatectomy

Clinical cancer research, 2017-05, Vol.23 (9), p.2169-2176

2017

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Characterization of a Bilirubin Inducible Green Fluorescent Protein From the Moray Eel Gymnothorax zonipectis

Frontiers in Marine Science, 2021-09, Vol.8

2021

Link zum Volltext

Verfügbarkeit prüfen

Disrupting Fluorescence by Mutagenesis in a Green Fluorescent Fatty Acid Binding Protein from a Marine Eel

The Protein Journal, 2020-04, Vol.39 (2), p.145-151

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies

Blood, 2009-11, Vol.114 (22), p.1711-1711

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies

Blood, 2008-11, Vol.112 (11), p.2108-2108

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)

Sprache

Erscheinungsjahr

n.n

Kollektion

EZB Free E-Journals
(17)
Publisher site
(13)
Journals@Ovid Complete
(7)
Ingenta
(6)
IngentaConnect Journals
(3)
Elsevier ScienceDirect Journals Complete
(2)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1)
Springer Nature - Complete Springer Journals
(1)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management

Force relaxes before the fall of cytosolic calcium in the photomechanical response of rat sphincter pupillae

Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC)

ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan

Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL

Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma

Abstract B216: Exposure-response (E-R) relationship of ABT-263-induced thrombocytopenia in cancer patients in phase 1 studies

Safety, Pharmacokinetics, Pharmacodynamics, and Activity of Navitoclax, a Targeted High Affinity Inhibitor of BCL-2, in Lymphoid Malignancies

Abstract 3738: Exploratory patient (pt) stratification markers associated with sensitivity to ABT-263 in small cell lung cancer (SCLC)

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Refractory or Relapsed Lymphoid Malignancies

Force relaxes before the fall of cytosolic calcium in the photomechanical response of rat sphincter pupillae

Neoadjuvant Enzalutamide Prior to Prostatectomy

Discovery and Characterization of a Bilirubin Inducible Green Fluorescent Protein From the Moray Eel Gymnothorax zonipectis

Disrupting Fluorescence by Mutagenesis in a Green Fluorescent Fatty Acid Binding Protein from a Marine Eel

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies

Suchergebnisse filtern